EGI
ANIP icon

EAM Global Investors’s ANI Pharmaceuticals ANIP Stock Holding History

EAM Global Investors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,243
Closed -$349K – 116
2019
Q2 		$349K Buy
+4,243
New +$302K 0.15% 124

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

EAM Global Investors's ANIP Position: Q3 2019 in Review

EAM Global Investors sold out of ANI Pharmaceuticals (ANIP) in Q3 2019, closing a stake of 4,243 shares — an estimated $349K sold.

EAM Global Investors first reported a position in ANIP in Q2 2019 and held it in 1 quarter. The position peaked at $349K in Q2 2019. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

  • EAM Global Investors reported no remaining ANI Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • EAM Global Investors sold 4,243 ANI Pharmaceuticals shares in Q3 2019, an estimated $349K.
  • EAM Global Investors first reported a position in ANI Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • EAM Global Investors's ANI Pharmaceuticals position peaked at $349K in Q2 2019.
  • 190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on EAM Global Investors's 13F filing for Q3 2019, filed 13 Nov 2019.